The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Diabetes and obesity are growing problems worldwide and are associated with a range of acute and chronic complications, including acute myocardial infarction (AMI) and stroke. Novel anti-diabetic medications designed to treat T2DM, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is), exert beneficial effects on metabolism and the cardiovascular system. However, the underlying mechanisms are poorly understood. GLP-1RAs induce anorexic effects by inhibiting the central regulation of food intake to reduce body weight. Central/peripheral administration of GLP-1RAs inhibits food intake, accompanied by an increase in c-Fos expression in neurons within the paraventricular nucleus (PVN), amygdala, the nucleus of the solitary tract (NTS), area postrema (AP), lateral parabrachial nucleus (LPB) and arcuate nucleus (ARC), induced by the activation of GLP-1 receptors in the central nervous system (CNS). Therefore, GLP-1RAs need to pass through the blood-brain barrier to exert their pharmacological effects. In addition, studies revealed that SGLT-2is could reduce the risk of chronic heart failure in people with type 2 diabetes. SGLT-2 is extensively expressed throughout the CNS, and c-Fos expression was also observed within 2 hours of administration of SGLT-2is in mice. Recent clinical studies reported that SGLT-2is improved hypertension and atrial fibrillation by modulating the "overstimulated" renin-angiotensin-aldosterone system (RAAS) and suppressing the sympathetic nervous system (SNS) by directly/indirectly acting on the rostral ventrolateral medulla. Despite extensive research into the central mechanism of GLP-1RAs and SGLT-2is, the penetration of the blood-brain barrier (BBB) remains controversial. This review discusses the interaction between GLP-1RAs and SGLT-2is and the BBB to induce pharmacological effects via the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“drugs like semaglutide have been shown to affect areas of the brain involved in the regulation of appetite and reward-seeking behaviors, including the hypothalamus, which can be exposed to semaglutide through tanycytes lining the ventricle wall that may help to regulate eating behaviors, thus contributing to an overall reduction in energy intake [15,16].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 6×
“Additionally, the activities of enzymes, transporters, and cytoskeleton proteins on BBB microvessels are preferentially suppressed in these DIO animals.110,111 Moreover, a study indicated that a high-energy (HE) diet is related to increased BBB permeability as elevations in peripheral proinflammatory cytokines comprom…”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 1×
“T2DM is a metabolic disorder characterized by long-term hyperglycemia and is one of the leading causes of morbidity and mortality.(1)”
BackgroundStructure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 1×
“Accumulating evidence demonstrates that obesity is not only strongly related to the etiology and pathogenesis of T2DM but also to the development of diabetic complications.(2) Hyperglycemia and”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The gut flora as a forgotten organ
O'Hara, A. M., & Shanahan, F. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400731 · Cited by 2,791
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530
A molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892 · cited 1×
“However, a study of single-cell RNA sequencing in the brain shows that the presence of GLP-1R on BBB endothelial cells is negligible.(37) Exenatide,(38) lixisenatide,(39,40) beinaglutide,(41) liraglutide,(42) dulagutide(43) and semaglutide(44) are now commercially accessible as GLP-1 receptor agonists (Table 1).”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 3×
“Although providing a first glimpse at the capacity of GLP-1RAs and SGLT-2is to traverse the BBB, the current review has not disclosed the specific signaling mechanisms, particularly for SGLT-2is.”
BackgroundInfluentialBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“former reduce postprandial blood glucose, while the latter affects both fasting and postprandial blood glucose.(6) In rodents, the anorexigenic effect of GLP-1RA administration peripherally requires central GLP-1R, for it is not inhibited in mice with central specific GLP-1R deletion.”
BackgroundCellular death, reactive oxygen species (ROS) and diabetic complications
Volpe, C. M. O., Villar-Delfino, P. H., dos Anjos, P. M. F., & Nogueira-Machado, J. A. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0135-z · Cited by 1,166
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Microbiota and diabetes: an evolving relationship
Tilg, H., & Moschen, A. R. (2014) · Gut · doi:10.1136/gutjnl-2014-306928 · Cited by 853 · cited 6×
“Additionally, the activities of enzymes, transporters, and cytoskeleton proteins on BBB microvessels are preferentially suppressed in these DIO animals.110,111 Moreover, a study indicated that a high-energy (HE) diet is related to increased BBB permeability as elevations in peripheral proinflammatory cytokines comprom…”
BackgroundInfluentialBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Obesity and neuroinflammation: A pathway to cognitive impairment
Miller, A. A., & Spencer, S. J. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.04.001 · Cited by 788
Fröhlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jačan, A., Wagner, B., Zinser, E., Bordag, N., Magnes, C., Fröhlich, E., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.02.020 · Cited by 720
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 2×
“Interestingly, semaglutide seems to be able to pass through the tanycytes that line the ventricular wall or areas lacking a BBB.(73)”
BackgroundMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 3×
“Some of the GLP-1RAs have been proven to cross through the BBB via passive diffusion.(34,46,48,68) In addition, GLP-1RAs could cross the BBB via the GLP-1 receptor-mediated uptake mechanism.”
BackgroundStentz, F. B., Umpierrez, G. E., Cuervo, R., & Kitabchi, A. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2079 · Cited by 497
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation
Abbott, N. J. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1374-y · Cited by 469
Involvement of ROS in BBB dysfunction
Pun, P. B. L., Lu, J., & Moochhala, S. (2009) · Free Radical Research · doi:10.1080/10715760902751902 · Cited by 457
Starr, J. M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.70 · Cited by 434
Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake
Heisler, L. K., Jobst, E. E., Sutton, G. M., Zhou, L., Borok, E., Thornton-Jones, Z., Liu, H. Y., Zigman, J. M., Balthasar, N., Kishi, T., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.06.004 · Cited by 429
Self-citationLin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423 · cited 1×
“In this context, the increase in cognitive function associated with empagliflozin and canagliflozin may also support the notion that these medicines are capable of penetrating the damaged BBB.(83) Inflammation in the CNS of patients with”
Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease
Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409 · cited 1×
“Dapagliflozin may enter the brain through impaired BBB, irrespective of its lipid-soluble properties, as evidenced by dramatically increased BBB permeability and disruption of tight junction between endothelial cells in Parkinson’s disease.(82) Empagliflozin improved cognitive performance in diabetic rats by lowering…”
BackgroundProbing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395 · cited 1×
“These drugs block SGLT-2 in proximal tubules, through which 90% of glucose is reabsorbed, thus decreasing the reabsorption of glucose and lowering the blood glucose levels.(8) In addition to the anti-diabetic effects, weight loss has also been observed in patients receiving SGLT-2i monotherapy.”
BackgroundMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347
Hawkins, B. T., Lundeen, T. F., Norwood, K. M., Brooks, H. L., & Egleton, R. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0485-z · Cited by 346
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Larsen, P. J. (1997) · Endocrinology · doi:10.1210/en.138.10.4445 · Cited by 316
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J. M., & Feder, J. N. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0006-4 · Cited by 307
Glaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305
Modulation of Gut Microbiota–Brain Axis by Probiotics, Prebiotics, and Diet
Liu, X., Cao, S., & Zhang, X. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b02404 · Cited by 304 · cited 1×
“the microbiota with prebiotics or probiotics benefits the host, while high-fiber diets also induce faster resolution of inflammatory responses.(118,119) Temporary disruption of BBB has been widely studied as a prevalent approach for delivering drugs into the CNS from the circulatory system.”
BackgroundNeuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction
Thackeray, J. T., Hupe, H. C., Wang, Y., Bankstahl, J. P., Berding, G., Ross, T. L., Bauersachs, J., Wollert, K. C., & Bengel, F. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.024 · Cited by 302
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 8×
“Numerous studies focusing on diverse brain illnesses such as Alzheimer’s disease (AD) and ischemic brain injury have corroborated the localization of GLP-1R in the CNS.32–34 In addition, a study reported GLP-1R expression on pericytes, which are multi-functional mural cells located at the center of the neurovascular u…”
BackgroundInfluentialThe role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287
Central and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Cosentino, F., Cannon, C. P., Cherney, D. Z. I., Masiukiewicz, U., Pratley, R., Dagogo-Jack, S., Frederich, R., Charbonnel, B., Mancuso, J., Shih, W. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050255 · Cited by 242
In-vitro blood-brain barrier models for drug screening and permeation studies: an overview
Bagchi, S., Chhibber, T., Lahooti, B., Verma, A., Borse, V., & Jayant, R. D. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s218708 · Cited by 234
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217 · cited 4×
“Kastin et al observed and analyzed the influx rate following intravenous injection of 125I-[Ser8] GLP-1.”
BackgroundInfluentialZhou, L., Sutton, G. M., Rochford, J. J., Semple, R. K., Lam, D. D., Oksanen, L. J., Thornton-Jones, Z. D., Clifton, P. G., Yueh, C.-Y., Evans, M. L., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.008 · Cited by 213
Self-citationHypertension and diabetes mellitus as a predictive risk factors for stroke
Alloubani, A., Saleh, A., & Abdelhafiz, I. (2018) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.009 · Cited by 210
Davidson, T. L., Monnot, A., Neal, A. U., Martin, A. A., Horton, J. J., & Zheng, W. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.05.015 · Cited by 200
Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 198
Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195
Shin, S. J., Chung, S., Kim, S. J., Lee, E.-M., Yoo, Y.-H., Kim, J.-W., Ahn, Y.-B., Kim, E.-S., Moon, S.-D., Kim, M.-J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165703 · Cited by 188
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
Rosenstock, J., Frias, J., Páll, D., Charbonnel, B., Pascu, R., Saur, D., Darekar, A., Huyck, S., Shi, H., Lauring, B., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13103 · Cited by 184
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Self-citationWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170 · cited 1×
“Lixisenatide has been demonstrated to pass the blood-brain barrier and exert neuroprotective effects in Alzheimer’s disease.(67) Hunter and Holscher reported increased cAMP levels in the CNS at all dosages after 30 minutes and 3 hours of lixisenatide injection, which indicated the activation of the GLP-1 receptor, and…”
BackgroundThe immune system's involvement in obesity-driven type 2 diabetes
Shu, C. J., Benoist, C., & Mathis, D. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.12.001 · Cited by 165
Blood Brain Barrier Injury in Diabetes: Unrecognized Effects on Brain and Cognition
Bogush, M., Heldt, N. A., & Persidsky, Y. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9752-7 · Cited by 165
Vieira, A. T., Galvão, I., Macia, L. M., Sernaglia, É. M., Vinolo, M. A. R., Garcia, C. C., Tavares, L. P., Amaral, F. A., Sousa, L. P., Martins, F. S., et al. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1015-453rrr · Cited by 163
Jensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., & Reimondo, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738848 · Cited by 143
Protein components of the blood–brain barrier (BBB) in the mediobasal hypothalamus
Gregory, E. N., Gömüç, B., & Meister, B. (2008) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2008.06.002 · Cited by 138
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131 · cited 1×
“BBB impairment has also been reported in a variety of neurological disorders, including Parkinson’s disease and Alzheimer’s disease.(22) Interestingly, oxidative stress is a common feature of all these cases.”
BackgroundFunctional expression of SGLTs in rat brain
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Basarah, E., Kepe, V., Satyamurthy, N., Huang, S., Wright, E. M., & Barrio, J. R. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2010 · Cited by 130
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127 · cited 1×
“Other studies have mapped the action of GLP-1RAs, demonstrating that GABA neurons in the NTS express GLP-1 receptors and mediate the anorectic effects of liraglutide in rats.(36) However, a study of single-cell RNA sequencing in the brain shows that the presence of GLP-1R on BBB endothelial cells is negligible.”
BackgroundRegional distribution of SGLT activity in rat brain in vivo
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Diez-Sampedro, A., Kepe, V., Satyamurthy, N., Huang, S.-C., Wright, E. M., & Barrio, J. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2012 · Cited by 126
Geiser, J. S., Heathman, M. A., Cui, X., Martin, J. A., Loghin, C., Chien, J. Y., & de la Peña, A. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0338-3 · Cited by 126
Acharya, N. K., Levin, E. C., Clifford, P. M., Han, M., Tourtellotte, R., Chamberlain, D., Pollaro, M., Coretti, N. J., Kosciuk, M. C., Nagele, E. P., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122254 · Cited by 121
Blood-brain barrier (BBB) and the complement landscape
Alexander, J. J. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.267 · Cited by 121
Amin, E. F., Rifaai, R. A., & Abdellatif, R. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12548 · Cited by 119
Madhumitha, H., Mohan, V., Deepa, M., Babu, S., & Aravindhan, V. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-1 · Cited by 118
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Oxidative Stress as the Leading Cause of Acute Myocardial Infarction in Diabetics
Filippo, C. D., Cuzzocrea, S., Rossi, F., Marfella, R., & D'Amico, M. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00077.x · Cited by 106
Serlin, Y., Levy, J., & Shalev, H. (2011) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2011/609202 · Cited by 104
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
Millar, P., Pathak, N., Parthsarathy, V., Bjourson, A. J., O’Kane, M., Pathak, V., Moffett, R. C., Flatt, P. R., & Gault, V. A. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0263 · Cited by 102
Luseogliflozin: First Global Approval
Markham, A., & Elkinson, S. (2014) · Drugs · doi:10.1007/s40265-014-0230-8 · Cited by 99
Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Self-citationSalinas, C. B. G., Lu, T. T.-H., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A. J., Cornea, A., Conradsen, K., Hecksher-Sørensen, J., Dahl, A. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28496-6 · Cited by 95
Hayden, M., Grant, D., Aroor, A., & DeMarco, V. (2019) · Brain Sciences · doi:10.3390/brainsci9030057 · Cited by 93
Gong, M., Wen, S., Nguyen, T., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s232377 · Cited by 92
Self-citationKalra, S., & Sahay, R. K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00894-y · Cited by 89
Diet-Induced Obesity Suppresses Expression of Many Proteins at the Blood–Brain Barrier
Ouyang, S., Hsuchou, H., Kastin, A. J., Wang, Y., Yu, C., & Pan, W. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.166 · Cited by 83
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
El-Sahar, A. E., Rastanawi, A. A., El-Yamany, M. F., & Saad, M. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118076 · Cited by 73
Rizvi, S., Shakil, S., Biswas, D., Shakil, S., Shaikh, S., Bagga, P., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660160 · Cited by 71
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70 · cited 1×
“dapagliflozin is a potent dual inhibitor of SGLT-2 and acetylcholinesterase, which could be used as the basis for future dual therapy for patients with diabetes and diabetes-related neurological disorders.(86) In 2014, the drug empagliflozin (EMPA) was approved for the treatment of T2DM.”
BackgroundLabouesse, M. A., Stadlbauer, U., Weber, E., Arnold, M., Langhans, W., & Pacheco‐López, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02364.x · Cited by 69
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Lin, K.-J., Wang, T., Chen, S., Lin, K.-L., Liou, C., Lan, M., Chuang, Y., Chuang, J., Wang, P., Lee, J., et al. (2021) · Antioxidants · doi:10.3390/antiox10121935 · Cited by 65
Chiba, Y., Sugiyama, Y., Nishi, N., Nonaka, W., Murakami, R., & Ueno, M. (2020) · Neuropathology · doi:10.1111/neup.12665 · Cited by 59
Banks, W. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200325110014 · Cited by 58
Lv, M., Xue, G., Cheng, H., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 58
Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 56
The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
Sha, W., Wen, S., Chen, L., Xu, B., Lei, T., & Zhou, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8867875 · Cited by 50
Self-citationZhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49
McGovern, S. F. J., Hunter, K., & Hölscher, C. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.029 · Cited by 47
Serotonergic pathways converge upon central melanocortin systems to regulate energy balance
Zhou, L., Williams, T. B., Lachey, J. L., Kishi, T., Cowley, M. A., & Heisler, L. K. (2005) · Peptides · doi:10.1016/j.peptides.2004.12.028 · Cited by 43
Self-citationLow-intensity focused ultrasound for the treatment of brain diseases: safety and feasibility
Toccaceli, G., Barbagallo, G., & Peschillo, S. (2019) · Theranostics · doi:10.7150/thno.31765 · Cited by 39
Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model
Arafa, N. M. S., Marie, M.-A. S., & AlAzimi, S. A. M. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.08.016 · Cited by 37
Wang, S., Jiao, F., Border, J. J., Fang, X., Crumpler, R. F., Liu, Y., Zhang, H., Jefferson, J. R., Guo, Y., Elliott, P. S., et al. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00438.2021 · Cited by 37
Brown, R. E., Gupta, N., & Aronson, R. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0134 · Cited by 35
Metabolic Syndrome and the Immunological Affair with the Blood–Brain Barrier
Mauro, C., De Rosa, V., Marelli-Berg, F., & Solito, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00677 · Cited by 34
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
Self-citationZhou, L., Yueh, C.-Y., Lam, D. D., Shaw, J., Osundiji, M. A., Garfield, A. S., Evans, M. L., & Heisler, L. K. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.043 · Cited by 29
Self-citationMatharu, K. S., Chana, K., Ferro, C. J., & Jones, A. M. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.867 · Cited by 20
Takeda, K., Ono, H., Ishikawa, K., Ohno, T., Kumagai, J., Ochiai, H., Matumoto, A., Yokoh, H., Maezawa, Y., & Yokote, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002104 · Cited by 19
Biswas, T., Gawdi, R., Jindal, C., Iyer, S., Kang, K. H., Bajor, D. J., Machtay, M. X., Choi, Y. M., & Efird, J. T. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1018 · Cited by 14
Wang, S., & Fan, F. (2019) · Hypertension · doi:10.1161/hyp.74.suppl_1.051 · Cited by 9
Tang, C., Li, Q., Deng, X., Wu, W., Liao, L.-F., Liang, K., Huo, R., Li, C., Han, J. D. J., Tang, W., et al. (2020) · RSC Advances · doi:10.1039/d0ra01002b · Cited by 8
Mishra, S. H., Bhavaraju, S., Schmidt, D. R., & Carrick, K. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114136 · Cited by 7
Abstract P729: Glp-1 Receptor Nitration Contributes to Brain Pericytes Dysfunction in Diabetes
Bailey, J., Barrett, A., Coucha, M. M., & Abdelsaid, M. A. (2021) · Stroke · doi:10.1161/str.52.suppl_1.p729 · Cited by 1
Research works printed but not linked: 2
- Bhavsar, 2013, Curr Diabetes Rev, 9, 161, 10.2174/1573399811309020007 · doi:10.2174/1573399811309020007 · Paper page
- Larsen, 1997, Endocrinology, 138, 4445, 10.1210/endo.138.10.5270 · DOI · Paper page
Cited by
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M. T., & Pandit, A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.035 · Cited by 119
GLP-1 Receptor Agonist Use and Risk of Suicide Death
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4369 · Cited by 103
Hölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 108
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 89
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
Metadata
- Authors
- Dong, M., Wen, S., & Zhou, L.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Zhou, Ligang
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-08
- Volume
- Volume 15
- Pages
- 2583-2597
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC9417299
- OpenAlex
- W4292553261
- Cited by
- 90
- References
- 122
- Citations by year
- 2026: 24 · 2025: 34 · 2024: 25 · 2023: 7
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Natural Science Foundation of Shanghai (ZHYY-ZXYJHZX-2-201712, PWR12014-06, 21675034, 19ZR1447500, 81370932)
- Wenzhou Medical University
- National Natural Science Foundation of China (81370932, PWR12014-06, 19ZR1447500, PWZzk2017-03, ZHYY-ZXYJHZX-2-201712, 21675034)
- Fudan University (Zdzk2020-24)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- blood-brain barrier, GLP-1 receptor agonists, SGLT2 inhibitors, type 2 diabetes, central nervous system, Fos expression, food intake regulation, paraventricular nucleus, renin-angiotensin-aldosterone system, sympathetic nervous system, hypertension, atrial fibrillation, chronic heart failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.